So, we’ll see how that all plays out. And again, the two wild cards, as I mentioned, BE-Smart esophageal cancer test. It’s not an operating business today. So, I don’t know how to judge the risk/reward, but I can tell you the test works. The clinical studies are fantastic. The results are fantastic. It is a sorely needed test which has no competition. And so, it seems like one way or another, it’s inevitable to be a very big deal. I just don’t know when but that’s a surprise factor. But when you have an underlying asset like Pharmaloz that could be worth more than the market cap of the company today. It certainly should be by the second half of this year. If you have that as the downside, and then you have Nebula that we’re investing in, the only reason we’re investing so aggressively, and the only reason we exited the clinical lab business was to build Nebula aggressively.
Just think about why we’re doing this. We’re not doing this to play games or tell stories. This is going to be very big. So, we just have a lot going on. I’m really excited about the future. I really appreciate all the long-term shareholders. Everything I do, I learned from my decades working on Wall Street. What’s the value of the company today divided by the number of shares outstanding? What’s the value of the company today divided by the number of shares outstanding? What’s the value of the company 123, and 5 years from now divided by the shares outstanding? Then I always think terminal value on a per share basis build the value of the company longer term. Back when we made a lot of money in COVID, didn’t know what to do with it. Stock came down, we bought back stock and paid special dividends.
Now, we’re investing and building a business because it’s got enormous growth. Two businesses have enormous growth potential, all right? What happens in the future when the revenues start to really take off again, who knows? A year from now, we could be paying special dividends and buying back stock again, or spinning off assets, or doing all kinds of fun things. That’s the goal, to get to the point where we’re back having fun again. I don’t think we’re too far away from that happening. I know it was a little long-winded today, but it’s only once a year that we get to have everybody together like this. The quarterly — we’ll probably do a quarterly call like this. Everybody can let me know if they like this format better using the Renmark. I certainly do Renmark VNDRs once a month.
If you want regular updates, reach out to Renmark and sign up. And then, separately on the quarterlies, we may continue to do them this way as well because that way I can show the slides and I think it’s better. Yes, I can’t hear your actual question, but I love working with Noella and she does a great job of asking questions anyway. With that, have a great day. I wish you all the best of luck. Noella, I hand it back over to you, and thank you.
Noella Alexander-Young: Thank you everyone for joining us today for the ProPhase Labs’ fourth quarter and year-end 2023 results. Once again, ProPhase is trading on the NASDAQ under the ticker symbol PRPH. Stay tuned for the next quarterly call, and see you next time.
